Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Metabolic disorders, including obesity, diabetes, and cardiovascular disease, are widespread in Westernized nations. Gut microbiota composition is a contributing factor to the susceptibility of an individual to the development of these disorders; therefore, altering a person's microbiota may ameliorate disease. One potential microbiome-altering strategy is the incorporation of modified bacteria that express therapeutic factors into the gut microbiota. For example, N-acylphosphatidylethanolamines (NAPEs) are precursors to the N-acylethanolamide (NAE) family of lipids, which are synthesized in the small intestine in response to feeding and reduce food intake and obesity. Here, we demonstrated that administration of engineered NAPE-expressing E. coli Nissle 1917 bacteria in drinking water for 8 weeks reduced the levels of obesity in mice fed a high-fat diet. Mice that received modified bacteria had dramatically lower food intake, adiposity, insulin resistance, and hepatosteatosis compared with mice receiving standard water or control bacteria. The protective effects conferred by NAPE-expressing bacteria persisted for at least 4 weeks after their removal from the drinking water. Moreover, administration of NAPE-expressing bacteria to TallyHo mice, a polygenic mouse model of obesity, inhibited weight gain. Our results demonstrate that incorporation of appropriately modified bacteria into the gut microbiota has potential as an effective strategy to inhibit the development of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While human and animal studies have established the ability to successfully populate the oral cavity or gastrointestinal tract with specific strains, combinations of bacteria, or bacteria genetically modified to produce enzymes or metabolites[74,404–407]”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [406]
Experimental — accuracy not yet measuredIn the citing paper
“Chen et al. demonstrated that an N-acylphosphatidylethanolamine (NAPE)-producing strain of EcN could significantly ameliorate symptoms associated with high-fat diet feeding in mice. Mice treated with this recombinant EcN displayed reduced adiposity, insulin resistance, and hepatosteatosis compared to animals treated with an unengineered EcN control37.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580 · cited 1×
“org Volume 124 Number 8 August 2014 Introduction Obesity dramatically increases the risks for cardiovascular disease and diabetes as well as other diseases, and rates of obesity have increased dramatically in the past 25 years (1, 2).”
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Changes in global gut microbiota, including an increased ratio of Firmicutes to Bacteroidetes, have been associated with obesity (9, 36–38).”
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936 · cited 1×
“However, mutations in these genes are rare in humans and cause extreme forms of obesity (39–41).”
Turnbaugh, P. J., Bäckhed, F., Fulton, L., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.015 · Cited by 2,915
Research works printed but not linked: 3
- Kramer, 1989, Int J Obes., 13, 123
- Wadden, 1989, Int J Obes., 13, 39
- Harris, 2012, J Obes., 2012, 879151
Cited by
Items 201–288 of 288
Interaction between the Microbiome and Diet: The Hologenome Concept
ROSENBERG, E. B., & Rosenberg, Z. (2016) · Journal of Nutrition & Food Sciences · doi:10.4172/2155-9600.1000545 · Cited by 6
“One example demonstrating the possibilities harbored in probiotics is the experiment carried out on mice fed a high-fat diet that contained in its water Escherichia coli that were genetically-engineered to produce N-acylphosphatidylethanolamines (NAPEs) [60].”
BackgroundThe ineluctable constraints of thermodynamics in the aetiology of obesity
Loiselle, D. S., & Barclay, C. J. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12869 · Cited by 6
“Chen et al.5 have demonstrated that presentation (via the drinking water) of therapeutically modified bacteria inhibits weight gain and fat deposition in mice fed a high- fat diet.”
BackgroundDesigner Probiotics in Metabolic Disorders
Gupta, R. G., & Raghuwanshi, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-8444-9_12 · Cited by 7
Principles, Tools, and Applications of Synthetic Consortia Toward Microbiome Engineering
Atkinson, E., Boo, A., Peng, H., Stan, G.-B. V., & Ledesma‐Amaro, R. (2022) · Wiley eBooks · doi:10.1002/9783527825462.ch7 · Cited by 6
Engineering commensal microbes for host health
Brown, E. A., Brevi, A., Zong, D. M., & Zarrinpar, A. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.025 · Cited by 4
Az emberi szervezetben élő baktériumok klinikai jelentősége a gyakorlatban
Fekete, M., Szarvas, Z., Fazekas‐Pongor, V., Fehér, Á., & Varga, J. T. (2021) · Egészségfejlesztés · doi:10.24365/ef.v62i4.6928 · Cited by 8
Deciphering Microbial Carbohydrate Metabolism: Unveiling Mechanistic Insights Into Type 2 Diabetes
Kumar, N., Sain, S., & Solanki, B. (2025) · Advanced Gut & Microbiome Research · doi:10.1155/agm3/4395850 · Cited by 5
“Furthermore, these recombinant bacteria can be programmed to respond to temporal signals like dietary factors [160].”
Genetically Engineered Probiotics
Hag, S., & Poondla, N. (2020) · Springer eBooks · doi:10.1007/978-981-15-8214-1_14 · Cited by 6
The Role of the Gut Microbiome in Bipolar Disorder and its Common Medical Comorbidities
Jones, G. H., Pinjari, O. F., Vecera, C. M., Smith, K., Barrera, A., & Machado‐Vieira, R. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101078 · Cited by 5
Zhou, L., Zhang, W., Li, Q., Cui, M., Shen, D., Shu, J., Mo, R., & Liu, Y. (2024) · Foods · doi:10.3390/foods13070974 · Cited by 4
“The incorporation of NAPE-producing bacteria into the gut slows the development of high-fat diet-induced obesity in wild-type mice [21] and improves cardio metabolic disease indicators in low-density lipoprotein null mice [22].”
BackgroundApplication of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-47405-2_136-1 · Cited by 4
Microbes as a Source for the Production of Food Ingredients
Gupta, C., & Prakash, D. (2017) · Wiley eBooks · doi:10.1002/9781119048961.ch6 · Cited by 4
Wang, Y., He, Y., Xie, J., Li, J., & Guo, J. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101719 · Cited by 4
“12–14 However, the intrinsic therapeutic potential of wild-type EcN in metabolic disorders and the precise mechanisms underlying its beneficial effects remain to be fully elucidated.”
Du, W., Zhang, C., Zou, Z., Shan, S., Wang, L., Jiang, W., Yin, B., Ye, B., & Zhou, Y. Q. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00815 · Cited by 3
Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health
Turco, F., Brugnatelli, V., & Abalo, R. (2023) · Medical Cannabis and Cannabinoids · doi:10.1159/000534007 · Cited by 3
“Conversely, a probiotic strain of Escherichia coli engineered to produce endocannabinoids can reduce adiposity in mice on a high-fat diet by suppressing food intake, improving insulin sensitivity, and reducing liver fi brosis [61].”
BackgroundMechanistic insights into postbiotics as therapeutic agents in type 2 diabetes management
Ebadpour, N., Faraji, N., Abavisani, M., Karav, S., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04456-6 · Cited by 5
“Another study similarly altered an E. coli strain to produce N-acylphos-phatidylethanolamines, demonstrating protection against obesity-related problems, including insulin resistance, in animal models (Chen et al. 2014).”
Gut Homeostasis; Microbial Cross Talks in Health and Disease Management
Khatri, G. S., Kurian, C., Anand, A., & Paari, K. A. (2021) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.9.3.28 · Cited by 3
Engineering live bacterial therapeutics to treat human diseases
Hwang, I. Y. (2023) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2023.100492 · Cited by 4
Industrial Production of Active Probiotics for Food Enrichment
Dalli, S. S., Uprety, B. K., & Rakshit, S. K. (2016) · Food engineering series · doi:10.1007/978-1-4939-6595-3_3 · Cited by 5
Recent Advances in Genetic Engineering Tools for Metabolic Engineering
Naidoo, J., Fok, E. T., Grobler, L., Molaoa, R. R., Nxumalo, Z., Selvamani, P., Latha, S., & Raj, D. B. T. G. (2020) · Springer eBooks · doi:10.1007/978-981-15-2604-6_6 · Cited by 3
Engineering Bacteria to Monitor the Bleeding of Animals Using Far-Red Fluorescence
Tan, Z., Li, X., Kong, C.-D., Sha, N., Hou, Y., & Zhao, K. (2021) · ACS Sensors · doi:10.1021/acssensors.0c02482 · Cited by 2
Mertz, L. (2017) · IEEE Pulse · doi:10.1109/mpul.2017.2701491 · Cited by 2
“To test how well the altered genes worked, they put all the experimental mice on a high-fat diet and divided them into four groups, of which only one received the drinking water with gelatin and NAPE-producing bacteria [4].”
BackgroundRole of the Microbiome in Cardiovascular Disease
Chaikijurajai, T., Wilcox, J. D., & Tang, W. H. W. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_15 · Cited by 2
Asghar, M. (2022) · Pure and Applied Biology · doi:10.19045/bspab.2022.110069 · Cited by 2
“coli Nissle 1917 bacteria in drinking water for 8 weeks successfully resulted in reduced levels of obesity even fed with a high-fat diet [49].”
BackgroundDiet and Gut Microbiota in Human Health
Hemalatha, R. (2016) · Revista de Fomento Social · doi:10.16943/ptinsa/2016/48878 · Cited by 2
Repurposing Microbes for Therapeutic Applications in Humans
Kim, K., Choe, D., Kang, M., Sung, B. H., Kim, H., Lee, S., Lee, D., & Cho, B. (2022) · Wiley eBooks · doi:10.1002/9783527825462.ch3 · Cited by 2
Zhang, J., Xu, J., Yin, J., Wang, X., Qi, Q., & Wang, Q. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00778 · Cited by 3
Harnessing Microbiome Therapy to Treat Metabolic Syndrome
Jnainati, M. A., Govindarajan, A., Tyagi, S., Iltaf, M., Jnainati, J. A., Ayoub, M., & Shadab, H. A. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.015 · Cited by 1
Using Probiotics Instead of Pharmaceuticals to Treat Gastrointestinal Disorders
Rowles, H. L. (2017) · Journal of Clinical Gastroenterology and Hepatology · doi:10.21767/2575-7733.1000023 · Cited by 2
“Probiotics are healthy bacteria that are a part of the human digestive tract; using them to treat gastrointestinal disorders and help return the gut to a state of homeostasis is preferable to introducing medications that will further eradicate the healthy gut bacteria and increase the risk of more serious gastrointest…”
BackgroundBergheim, I., & Glei, M. (2015) · Die Gastroenterologie · doi:10.1007/s11377-014-0966-4 · Cited by 1
Genetically engineered microbes for sustainable therapies
Sharma, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820528-0.00009-0 · Cited by 1
An acetoacetate-inducible bacterial sensor
Gonzales, D., Ozdemir, T., Thomas, G., & Barnes, C. P. (2016) · UCL Discovery (University College London) · Cited by 1
Kirupananthan, A. (2015) · Gastrointestinal Nursing · doi:10.12968/gasn.2015.13.10.48
Programming microbes to treat superbug infection
Wong, C. K. A. (2014) · doi:10.25560/31369
Mikrobiom, Adipositas und Energiestoffwechsel
Chakaroun, R., & Blüher, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0123-4
Reversing the De-Evolution of Our Gut Flora to Combat Obesity and its Comorbidities
Rowles, H. L. (2017) · Journal of Nutrition & Weight Loss · doi:10.35248/2593-9793.17.2.106
“Clinical implications of this research are that effective treatments for the reduction and prevention of obesity could be enhancing the density and diversity of the gut microbiome through probiotic supplementation and bacteriotherapy [1,7,12,23,25].”
BackgroundTargeting the Gut Microbiome to Ameliorate Cardiovascular Diseases
Hwang, S., Park, C. O., & Rhee, K. (2017) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2017.23.3.166
“예를 들자면, N-acylphosphatidylethanolamines 를 발현하는 Escherichia coli Nissle 1917 균주는 고지방식 으로 유도되는 비만을 경감 및 완화시킬 수 있는 유전적 으로 조작된 균주 중 하나로 알려져 있다(Chen et al., 2014).”
Ibrahim, A. M., & Smith, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/206227
Bacteria, Viruses, and the Microbiome
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00020-x
Revealing gut microbiota metabolism with dietary glycan-fluorophore conjugates
Altamura, F. (2019) · eScholarship@McGill (McGill) · doi:10.82308/45005
Expanding the bio-capabilities of Lactococcus lactis through efficient genome modification
Rothstein, S. M. (2020) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210114-128
Engineering and characterization of probiotics to tackle fructose-induced metabolic syndrome
Au-Yeung, B. S. Y. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/144733 · Cited by 1
Role of CRISPR/Cas9 and other gene editing/engineering technology in intestine diseases
Yang, Y., & Cheng, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821269-1.00011-4
Critical Inspection of the Gut–Brain–Skin Triangle and Its Modulation Through Probiotics
Chugh, P., Sood, S., & Dhar, M. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_2
Wagner, A. (2018) · gynäkologie + geburtshilfe · doi:10.1007/s15013-018-1551-6
Bockaert, J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.730126536.793537627
(2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811351-6.00026-7
Programming microbes to treat superbug infection
Wong, A. C. K. (2016) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/65950
Exploring the Potential of Microbial Engineering: The Prospect, Promise, and Essence
Patra, S. D., Arunima, A., & Suar, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_1
Affordable Therapeutics Through Engineered Microbes
Sahoo, S., & Misra, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_15
A Tour-d’Horizon of microbiota therapeutics for metabolic disorders
Saifi, S., Swaminathan, A., Devi, P., Chattopadhyay, P., Gupta, S., Garg, A., Saxena, S., Parveen, S., & Pandey, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00006-9
Microbiome therapeutics as an alternative to the antibiotics
Singh, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00004-5
Applications of Microbial Fermentation to Food Products, Chemicals and Pharmaceuticals
Lee, B. H. (2021) · Wiley eBooks · doi:10.1002/9781119042792.part2
Genetiği Değiştirilmiş Probiyotikler
Çıldır, Ö. Ş. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub358.c1516
Adjuvant Effect of Probiotics in the Treatment of Periodontal and Peri-Implant Diseases
Barbagallo, G., Monaca, G., Gregorio, F. D., Alì, G., Porto, V., & Assenza, G. (2024) · Dentistry · doi:10.5772/intechopen.1005784
Microbiome engineering in human health
Zhang, B., Zhou, Z., Yang, M., & Chen, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22348-8.00001-5
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Designer Probiotics and Postbiotics
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_25
Plant molecules in obesity and the gut microbiota
Eslami, M., Bahar, A., Alipour, T., Hemati, M., Nouri, A., Babaeizad, A., Golpayegani, E., & Bineshjoo, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00029-9
Synthetic biology and genetic engineering in pharmaceutical bioprospecting
Kant, S., Roy, S., & Sarkar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33032-2.00019-8
Zumwalt, M., Croom, M., Walzem, R. L., & Oladokun, S. (2025) · The Journal of Applied Poultry Research · doi:10.1016/j.japr.2025.100647
Yadav, S., & Tripathi, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30060-8.00018-2 · Cited by 1
Bai, L., Gao, M., Cheng, X., Kang, G., Cao, X., & Huang, H. (2020) · Figshare · doi:10.6084/m9.figshare.12197469
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558360
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558342
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558351
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558366
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. Ø., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558336
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558354
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558363
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558348
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558357
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558345
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558339
Engineered bacteria: a novel era for metabolic, cardiovascular and cerebrovascular diseases therapy
Wu, Y., Sang, R., Chen, X., & Wang, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1757348
“The production of engineered bacteria compensates for the lack of the potent anorexic lipid family N-acyl phosphatidylethanolamine (NAPEs) (15).”
Etude et caractérisation des vésicules extracellulaires dans un contexte d’obésité
Amosse, J. (2019) · theses.fr (ABES) · doi:10.70675/2d90fa73z378bz47bdza83cz809db70f24fb
Hutchinson, N. T., Ye, N., Jennings, M., Fang, C., Qi, N., & Li, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.716956
Tagliamonte, S., Neill, H. R., Murphy, B., Pourshahidi, L. K., Filippis, F. D., Ercolini, D., Gill, C., Koós, N., Curran, B. P. G., Murray, N., et al. (2026) · Food & Function · doi:10.1039/d5fo03328d
Development strategies for engineered live biotherapeutic products for metabolic diseases
Yun, S., Choi, K.-S., Min, H., Jo, Y. K., & Jang, S. (2026) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2026.2653692 · Cited by 1
“[27] butyric acid, or leptin, which induce antiobesity effects [39,45,103].”
Hu, X., Chen, Y., Jin, M., Xiong, Q., Ren, J., & Duan, H. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c08082
Lim, E., Cheng, N. C. L., & Lim, C. E. D. (2026) · Nutrition & Food Science · doi:10.1108/nfs-05-2026-0239
Evbuomwan, E. M., Khanna, S., Xi, C., Rottinghaus, A. G., Ferreiro, A. L., Kwak, S., Butler, B., Ning, J., Najari, J., Liao, J., et al. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.09.007
Wnt signaling arranges the fate of lipid metabolism: The role of gut microbes
He, C., 刘春忻, Li, Y., Yin, J., Ma, J., & Yin, Y. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100039
Gao, Y., Gao, X., Wang, K., Qiao, J., & Jiang, C. (2026) · Science China Life Sciences · doi:10.1007/s11427-026-3413-3
Gut Microbiota: Little Things Making a Big Difference
Kazi, E. (2014) · Berkeley Scientific Journal · doi:10.5070/bs3191025156
Metadata
- Authors
- Chen, Z., Guo, L., Zhang, Y., L. Walzem, R., Pendergast, J. S., Printz, R. L., Morris, L. C., Matafonova, E., Stien, X., Kang, L., Coulon, D., McGuinness, O. P., Niswender, K. D., & Davies, S. S.
- Affiliations
- Vanderbilt University (US)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Davies, Sean S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-06-24
- Volume
- 124
- Issue
- 8
- Pages
- 3391-3406
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4109548
- OpenAlex
- W2076877166
- Cited by
- 277
- References
- 76
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 19 · 2023: 22 · 2022: 31 · 2021: 26 · 2020: 26 · 2019: 22 · 2018: 18 · 2017: 35 · 2016: 29 · 2015: 23 · 2014: 3
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- National Institutes of Health (1dp2od003137-01, 5p60dk020593-31)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK020593, U24DK092993, DK59637, DK 20593, U24DK059637, P30DK058404, P30DK020593)
- National Center for Research Resources (UL1RR024975)
- National Center for Complementary and Integrative Health (R01AT007830, AT07830)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- obesity, gut microbiota, engineered bacteria, N-acylphosphatidylethanolamine, Escherichia coli Nissle 1917, high-fat diet, dietary intake, insulin resistance, hepatic steatosis, metabolic disorders, microbiome engineering
- MeSH terms
- Acyltransferases, Animals, Digestive System, Disease Models, Animal, DNA-Binding Proteins, Eating, Escherichia coli, Female, Humans, Liver, Male, Mice, Inbred C57BL, Obesity, Phosphatidylethanolamines, Recombinant Proteins, Weight Gain, Arabidopsis Proteins, Mice, Diet, High-Fat, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.